Salute e Benessere

Hisense Unveils Glass Door Refrigerators in the GCC, Elevating Everyday Living…

As part of the Hisense REFLECT Series, these refrigerators transform everyday kitchen essentials into design statements. Featuring multi-layered, tempered glass doors, they combine durability with a high-gloss finish that resists scratching and fading. The result is a sleek, sophisticated focal point that enhances any contemporary kitchen. As part of the Hisense REFLECT Series, these refrigerators transform everyday kitchen essentials into design statements. Featuring multi-layered, tempered...
PR Newswire
30/04/2025

Illuccix Prostate Cancer PSMA-PET Imaging Agent Approved in Finland

PSMA-PET imaging represents a significant advancement in prostate cancer management, largely replacing conventional imaging methods (bone scan, CT[4] scan) as the standard of care after initial diagnosis and biochemical recurrence (BCR). Global guidelines highlight the superior accuracy of PSMA-PET for the staging of primary disease and evaluation of BCR/biochemical persistence (BCP)[5]. Illuccix® PSMA-PET will help fulfil a critical unmet need by facilitating access to timely and effective…
PR Newswire
30/04/2025

Zelluna ASA: Invitation to First Quarter 2025 results webcast presentation

Oslo, Norway, 30 April 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic 'off the shelf' T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, invites to a webcast presentation of its first quarter 2025 results, on Thursday, May 8, 2025 . The presentation can be followed as a live webcast accessed through a link on www.zelluna.com at 09:00 CET on Thursday, May 8, 2025. The webcast presentation will be available on the Zelluna website, and it will be...
Nasdaq GlobeNewswire
30/04/2025

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study…

Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or borderline resectable pancreatic cancer to be presented by Principal Investigator Eugene Koay, MD, at ESTRO 2025 on Sunday, May 4 that 11:00 AM EDT / 5:00 PM CESTNanobiotix will host an event on Monday, May 5 that 8:00 AM EDT / 2:00 PM CEST to review the presented results PARIS and CAMBRIDGE, Mass...
Nasdaq GlobeNewswire
30/04/2025

J INTS BIO Presents Research Results for Next-Generation Innovative Anticancer…

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases worldwide, and among these, EGFR mutations are considered a major therapeutic target. JIN-A02, introduced at AACR 2025, showed outstanding therapeutic efficacy in patients who developed resistance to existing third-generation EGFR-TKIs. In particular, JIN-A02 demonstrated remarkable antitumor activity in patients with EGFR C797S mutation—currently a mutation for which no approved targeted therapies…
PR Newswire
30/04/2025

Nicox Provides Full Year 2024 Financial Results

Press ReleaseNicox Provides Full Year 2024 Financial Results Nicox SA revenue of €7.9 million for full year 2024 Exceptional income of €13.7 million following the transfer of VYZULTA's future revenue stream to Soleus CapitalNicox SA cash of €10.5 million on 31 December 2024 and the Company estimates it is currently financed into the fourth quarter of 2025 Topline results from NCX 470 second Phase 3 clinical trial, Denali, expected in the third quarter of 2025...
Nasdaq GlobeNewswire
30/04/2025

Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer…

Immuno-Oncology Results from Research Collaboration withLéon Bérard Cancer Center Presentedat AACR Annual Meeting 2025New gene expression signature for cancer patients to predict clinical response toimmune checkpoint.Potential of signature to enhance personalized treatment for patients, regardless of cancer type.NANTES, France – April 30, 2025, 7:30 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing...
Nasdaq GlobeNewswire
30/04/2025

Navamedic Q1 2025: Strong start of the year and well-positioned for future…

"After investing in several strategic growth initiatives last year, we are pleased to see strong results already in the first quarter of 2025. The positive impact of the Nordic tender wins for our antibiotics portfolio has just begun to materialize. In addition, several products, including Mysimba® and Imdur® from our Prescription Drugs (RX) segment, delivered strong performance in the quarter," said Kathrine Gamborg Andreassen, CEO of Navamedic. "After investing in several…
PR Newswire
30/04/2025

Addex Enters Option Agreement with Sinntaxis for an Exclusive License to…

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2025-Addex Therapeutics(SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it has entered into an option- and collaboration agreement with Sinntaxis AB ( www.sinntaxis.com ) for an exclusive license to intellectual property covering the use of metabotropic glutamate receptor...
Nasdaq GlobeNewswire
30/04/2025

CHMP recommends EU label update for Roche's Phesgo to allow administration…

Positive recommendation based on clinical, real-world and bioequivalence data supporting feasibility and safety of Phesgo's administration outside of clinical settings, for example at home 1-4 Phesgo label expansion delivers on patients' preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings 3 Phesgo has the potential to reduce treatment administration costs by up to 80% in Western Europe, and 85% of patients prefer SC...
Nasdaq GlobeNewswire
30/04/2025

Sandoz reports Q1 2025 net sales in line with company expectations; full-year…

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASEQ1 2025 net sales of USD 2,480 million up by 3% in constant currencies (cc); stable in USDup by 5%[1] at a comparable growth rate (CGR), when adjusted for impact of 2024 acquisition of US biosimilar Cimerli® (ranibizumab) and 2024 divestment of China businessten largest-selling medicines grew by combined 4% and represented 33% of net salesEurope net sales grew by 7%[1]. International...
Nasdaq GlobeNewswire
30/04/2025

Idorsia announces financial results for the first quarter 2025 – QUVIVIQ taking…

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – April 30, 2025Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2025. Business highlights Q1 2025 QUVIVIQ™ (daridorexant): Strong performance and accelerating sales in Q1 2025 with total Idorsia-led net sales of CHF 25 m. QUVIVIQ EUCAN:Demand grew by 50% from Q4 2024 to Q1 2025, strongly driven by reimbursed markets. Overall, more than 10 million nights of sleep prescribed in...
Nasdaq GlobeNewswire
30/04/2025

137th Canton Fair Phase 2 Highlights Quality Home Life Through Innovation and…

One standout comes from EKO Group Ltd., which exhibited a semi-round smart sensor bin that exemplifies the fusion of design and technology. This model features motion-activated, hands-free operation, a silent-closing lid, a removable inner bucket for easy cleaning, and a fingerprint-resistant stainless-steel body. Its sleek design reflects a growing consumer desire for functional products that elevate both hygiene and style in everyday spaces. One standout comes from EKO Group Ltd., which...
PR Newswire
30/04/2025

FABHALTA Set to Disrupt Complement Inhibitor Market with Oral Convenience and…

Novartis' FABHALTA (iptacopan) Overview Novartis' FABHALTA (iptacopan) Overview Iptacopan is an innovative, first-in-class oral small molecule that reversibly inhibits factor B—a crucial serine protease in the alternative pathway of the complement system. By targeting this point upstream of the C5-terminal pathway, iptacopan effectively prevents both intravascular and extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria (PNH). Its selective mechanism allows it to...
PR Newswire
29/04/2025

GENFIT Announces Publication of the 2024 Universal Registration Document and the…

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces the filing of its 2024 Universal Registration Document with the Autorité des marches financiers (AMF ; filing n° D.25-0331) and its Annual Report on Form 20-F for the year ended December 31, 2024 with the U.S. Securities and...
Nasdaq GlobeNewswire
29/04/2025

Biomarkers Market to Grow at 13.1% CAGR from 2024 to 2029

The report covers the market's size, growth trends, product types, technologies, therapeutic areas, and end-users. It includes instruments, consumables, services, software, and technologies such as genomics, proteomics, metabolomics, imaging, and bioinformatics. The report also examines therapeutic areas such as cancer and cardiovascular diseases and end users such as academic institutions and hospitals. It covers North America, Europe, Asia-Pacific, and the Rest of the World and profiles…
PR Newswire
29/04/2025

Casino Group: FIRST-QUARTER 2025

FIRST-QUARTER 2025The New Casino rolls out its strategic plan Streamlining of the convenience brands store networkExit of 466 outlets from the store network, opening of 31 stores and transfer of 18 integrated stores to franchises or business leases over the quarterAccelerated roll-out of new concepts Franprix's "Oxygène" concept extended to 16 new stores Naturalia's "La Ferme" concept rolled out to 5 new stores Inauguration of the first three Monoprix "La…
Nasdaq GlobeNewswire
29/04/2025

Casino Group: Monoprix and the Zouari family plan to franchise 27 Monop' stores

Monoprix and the Zouari family plan to franchise 27 Monop' stores Monoprix, a Casino Group brand, and the Zouari family plan to franchise in the Joint Venture common to Monoprix and the Zouari family, 27 Monop' stores in Paris and the Île-de-France region. This transaction is part of Monoprix's strategy to step up sales momentum in its network and accelerate its development with the support of a long-standing partner.The project includes a renovation plan to bring the stores up to the...
Nasdaq GlobeNewswire
29/04/2025

EssilorLuxottica: Disclosure of transactions in own shares

Disclosure of transactions in own shares Paris, France (April 29, 2025 - 6:00 pm)– In accordance with the authorization granted by the Annual Shareholders' Meeting on April 30, 2024, EssilorLuxottica declares that from April 22, 2025, to April 28, 2025, inclusive, the following share buybacks were carried out: Name of the issuerIdentity code of the IssuerDay of the transactionIdentity code of the financial instrumentTotal daily volume (in number of shares)...
Nasdaq GlobeNewswire
29/04/2025

Wound Care Market Size to Hit $29.57 Billion by 2030 - Grand View Research, Inc.

The number of incidences of burn wounds globally has been increasing annually, leading to the growing demand for wound care. As per a report, the number of patients treated for burn injuries is approximately 450,000 annually. Advanced dressings, moisturizers, and ointments play an important role in the treatment of burn injuries. These products help with faster recovery of burn wounds and promote better wound healing. The frequent occurrence of diabetic foot ulcers (DFUs) caused due to diabetes…
PR Newswire
29/04/2025

Navamedic ASA: Imdur® distribution agreement extended to 2032

Imdur® (isosorbide mononitrate), is a prescription medication used to prevent angina pectoris due to heart disease. It was first launched in Europe in 1985. Navamedic commenced distribution of the product as part of a strategic partnership and long-term distribution agreement with TopRidge Pharma Limited in 2016. Imdur® (isosorbide mononitrate), is a prescription medication used to prevent angina pectoris due to heart disease. It was first launched inEuropein 1985. Navamedic commenced...
PR Newswire
29/04/2025

Combined General Meeting of May 21, 2025 - Availability of preparatory documents

Press Release Paris – April 29, 2025– EUROAPI's shareholders are invited to attend the Combined General Meeting to be held on Wednesday May 21, 2025 at 10:30 a.m. (CET) at 15 bis, rue Traversière 75012 Paris.The notice of meeting was published at the French official legal announcement publication (BALO) on Wednesday April 16, 2025 and the convening notice ( avis de convocation ) was published in the Actu-juridique.fr, a French journal of legal notice, on April 28, 2025...
Nasdaq GlobeNewswire
29/04/2025

Clinical AI Platforms Expand Globally Amid Regulatory and Market Tailwinds

VANCOUVER, BC, April 29, 2025 /PRNewswire/ -- Across the western healthcare landscape, artificial intelligence (AI) is being increasingly adopted to simplify authorizations and cut through layers of bureaucratic inefficiency. Rather than replacing physicians — a scenario some tech leaders like Bill Gates have speculated about — the goal is to enhance the capabilities of healthcare professionals. Momentum in this space is being driven by recent initiatives from companies like Avant Technologies…
PR Newswire
29/04/2025

New Advances in Healthcare AI Could Unlock Billions in Market Opportunity

VANCOUVER, BC, April 29, 2025 /PRNewswire/ -- Artificial intelligence is making deeper inroads into western healthcare, targeting the slow grind of authorizations and paperwork that bog down patient care. Despite Bill Gates' prophecy about AI replacing doctors, the real push today is about supercharging physicians, not sidelining them. Recent moves by players such as like Avant Technologies, Inc. (OTCQB: AVAI), Amesite Inc. (NASDAQ: AMST), Oracle Corporation (NYSE: ORCL), Clover Health…
PR Newswire
29/04/2025
Altri  Comunicati